IOVA stock climbs over 10% after multiple insider purchases (NASDAQ:IOVA)
seekingalpha.com
finance
2022-06-03 16:14:08

CalypsoArt/iStock via Getty Images Cancer-focused biotech Iovance Biotherapeutics, (NASDAQ:IOVA) surged over 15% in the morning hours Friday to record the biggest intraday gain in over a year after several insider purchases at the company. The buyers included Iovance's (IOVA) general counsel Frederick Vogt who was appointed as the company's interim Chief Executive last year following the resignation of his predecessor Maria Fardis. Purchasing 1,000 Iovance (IOVA) shares at $6.44 apiece Vogt has started an equity position at the company on May 31, according to a regulatory filing.
